U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Science & Research
  3. FDA Technology Transfer Program
  4. Licensing and Collaboration Opportunities
  5. Solid-phase Purification of Synthetic DNA Sequences
  1. Licensing and Collaboration Opportunities

Solid-phase Purification of Synthetic DNA Sequences

Download the Abstract (PDF - 95KB)

Technology Summary

FDA researchers have developed a novel high-throughput method for purifying full-length phosphorothioate and native DNA sequences. This method comprises a modified silica gel that enables capture of DNA sequences functionalized with a novel linker specifically designed for exclusive capture of full-length sequences. This technology can generate DNA sequences of high purity without the need of expensive equipment and associated accessories. This discovery may improve the availability of pure DNA sequences for clinical and/or synthetic biology applications.

Potential Commercial Applications Competitive Advantages
  • A high-throughput purification technique for producing small and large quantities of highly pure DNA sequences.
  • Cost effective
  • High-throughput capabilities
  • Time-saving
  • High purity

Development Stage: in vitro data

Inventors: Serge Beaucage, Andrzej Grajkowski

Publications:
“Solid-Phase Purification of Synthetic DNA Sequences.” J. Org. Chem. 2016 Aug 5;81(15):6165-75 PMID: 27382974

Intellectual Property:
PCT/US2017/039720,  filed 6/28/17
United States patent application: 16/312,445, filed 12/21/2018

Product Area: Drugs

FDA Reference No:E-2016-005

Licensing Contact:
FDA Technology Transfer Program
Email: FDAInventionlicensing@fda.hhs.gov

Back to Top